TY - JOUR
T1 - NAFLD
T2 - A pretransplant and post-transplant conundrum
AU - Rodas, Fabian V.
AU - Shankar, Nagasri
N1 - Publisher Copyright:
© 2023 John Wiley and Sons Inc.. All rights reserved.
PY - 2023/4
Y1 - 2023/4
N2 - The management of NAFLD may be uniquely challenging as conventional strategies, such as calorie restriction and rapid weight loss, may not be feasible in advanced disease states. The optimization of metabolic dysfunction requires a multidisciplinary approach with the use of pharmacotherapy that favors glycemic and cardiometabolic risk benefits. Surgical and medically achieved weight loss in LT candidates also raises concern for precipitating liver decompensation. However, gastric sleeve may be an option for highly selected patients with compensated disease in centers with expertise in BS (Figure 2). Management of post-LT NAFLD is equally complex. There is a paucity of society guidance on how to prevent de novo and recurrent NAFLD and manage comorbidities in these patients. After LT, the maintenance of weight loss and reduction of comorbidities may be achieved with the same antidiabetic agents as in the pre-LT setting. Alterations in immunosuppressive regimens, such as minimization of CNIs, may also reduce weight gain and post-LT diabetes.
AB - The management of NAFLD may be uniquely challenging as conventional strategies, such as calorie restriction and rapid weight loss, may not be feasible in advanced disease states. The optimization of metabolic dysfunction requires a multidisciplinary approach with the use of pharmacotherapy that favors glycemic and cardiometabolic risk benefits. Surgical and medically achieved weight loss in LT candidates also raises concern for precipitating liver decompensation. However, gastric sleeve may be an option for highly selected patients with compensated disease in centers with expertise in BS (Figure 2). Management of post-LT NAFLD is equally complex. There is a paucity of society guidance on how to prevent de novo and recurrent NAFLD and manage comorbidities in these patients. After LT, the maintenance of weight loss and reduction of comorbidities may be achieved with the same antidiabetic agents as in the pre-LT setting. Alterations in immunosuppressive regimens, such as minimization of CNIs, may also reduce weight gain and post-LT diabetes.
UR - http://www.scopus.com/inward/record.url?scp=85159818985&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85159818985&partnerID=8YFLogxK
U2 - 10.1097/CLD.0000000000000021
DO - 10.1097/CLD.0000000000000021
M3 - Review article
C2 - 37936953
AN - SCOPUS:85159818985
SN - 2046-2484
VL - 21
SP - 93
EP - 98
JO - Clinical Liver Disease
JF - Clinical Liver Disease
IS - 4
ER -